1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

  • July 2014
  • 122 pages
  • Firstword Pharma
Report ID: 2185201

Summary

Table of Contents




There has been considerable media hype and clinical interest in cancer immunotherapy in recent years. Indeed, there is talk of late stage cancers such as melanoma and NSCLC being managed as chronic conditions with significant increases in life expectancy. There is even speak of a cure.

But what is the true state of cancer immunotherapy research? Can we really be sure that the promise of early-stage success will be seen in late-stage clinical trials? Importantly, what do leading clinicians think about the products and research and how do they see things playing out in the clinical setting?

Undoubtedly, few research developments in recent years have held such promise to provide game a game changing shift in the treatment of cancer. Ever since the launch of Dendreon’s Provenge (sipuleucel-T) and, more recently BMS’ checkpoint inhibitor Yervoy (ipilimumab), there has been growing knowledge and anticipation that we are on the cusp of a radical new era of cancer management. As one leading KOL puts it “this is nothing less than an explosion in the options for our patients”

Opportunities and challenges

Immediate research interest is focussed on the CTLA-4L, PD1 and PD-L1 classes, with many expected to market in the medium term in a battle between BMS, Merck, Roche and AZ among others. The PD-1 products have shown high-levels of efficacy in trials leading to hitherto unseen therapeutic outcomes in melanoma and NSCLC with the prospect of wider indications to follow as research advances.

But there are challenges too. The expected high costs of therapy will need to be mitigated by the development and use of accurate diagnostic biomarkers – an area still lagging in significant progress. Moreover, current clinical trial protocols are felt to be inappropriate for assessing immunotherapeutics. The disappointing results from Dendreon’s Provenge have brought into question the value and role cancer vaccines might play in the treatment mix, though research is ongoing.

It is still early days. How immunotherapeutics will be best utilised is still open to question, though application in combination with other agents and treatment regimes seems to yield the best results.

The bottom line here is that cancer immunotherapies will revolutionise cancer treatment and the fortunes of the companies who bring effective and safe products to the market.









Key benefits, features and insights

The cancer immunotherapy market is evolving rapidly. In this report, key stakeholders from the pharmaceutical industry, diagnostic biomarker developers, regulatory authorities and health payers will:

Gain access to the latest research developments and KOL expert views on current and future
products and how they will fit into cancer treatment regimes with trends across a range of topics, from competitive strategy, clinical development, IP, and pricing


Appreciate the practical insights of practicing clinicians

Understand the regulatory issues which could negatively affect progress and why new clinical trial protocols are required

Be aware of the very latest clinical research results from ASCO 2014

Learn about the clinical benefits and challenges for CTLA-4L, PD1 and PD-L1 therapeutic approaches including efficacy and toxicity assessments

Understand how cancer vaccines may fit into the future market

Gain insight to the different types of combination therapies which are being examined to secure maximum therapeutic benefit

Key Features

Extensive examination of the therapeutic approaches and products in research
Detailed assessment of launched products
Current and extensive clinical trial status and results
Critical appraisal of research environment related to issues such intellectual property, pricing and biomarkers
Insightful commentary and opinions from leading KOLs

Key Insights

Which companies are leading the race to be first to market and with what products?
How might toxicity affect take up?
What type of patients will benefit most?
What challenges need to be overcome in the education of clinicians and patients?
How regulators need to develop their product review systems when assessing cancer immunotherapies
When will the price be too high: balancing the cost/benefit equation?



KOL Panel

Incisive questions. Expert answers. Critical insights


This report examines the key developments in cancer immunotherapy and examines the research and products that are the focus of attention. It includes from the most prominent cancer KOL’s in Europe and the US whose knowledge and practical clinical experience and involvement means their insights and opinions need to be considered carefully by drug developers.



Dirk Schadendorf, MD, Director for the Dermatology Clinic, University of Essen, Essen, Germany
Hossein Borghaei, DO, Chief, Thoracic Medical Oncology, Director, Lung Cancer Risk Assessment, Fox Chase Cancer Center, Philadelphia, PA, USA
Julie R. Brahmer, MD, MSc Associate Professor of Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, Baltimore, MD, USA
Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Washington DC, USA
Michael Postow MD. Assistant Attending Physician, Melanoma-Sarcoma Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Paolo A. Ascierto, MD, Cancer Immunotherapy and Innovative Therapy Unit Istituto Nazionale Tumori Fondazione ‘G. Pascale,' Naples, Italy
Anonymous, Lung cancer specialist, Los Angeles, CA, USA
Anonymous, Melanoma specialist, Pittsburgh, PA, USA




Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Therapeutic Vaccines Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global therapeutic vaccines market was valued at USD 11 billion in 2015 and is projected to reach USD 51 billion by 2021, at a CAGR of 29% during the forecast period. The increasing prevalence of chronic ...

Cancer Vaccines Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • $ 3840
  • Industry report
  • July 2017
  • by Allied Market Research

A vaccine is a biological preparation that strengthens the immune system and provides acquired immunity against a specific pathogen. According to the World Health Organization (WHO), cancer vaccines are ...

Global Cancer Vaccine Partnering 2010-2017: Deal trends, players, financials and forecasts

  • $ 2995
  • Industry report
  • September 2017
  • by Currentpartnering

The Global Cancer Vaccine Partnering 2010-2017 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market

  • September 2017
    12 pages
  • Therapy  

    Targeted Therap...  

View report >

Therapy Market and Cancer Immunotherapy Market in Canada

  • August 2017
    63 pages
  • Therapy  

    Cancer Immunoth...  

    Chemotherapy  

  • Canada  

View report >

Therapy Market in the US

  • August 2017
    8 pages
  • Therapy  

  • United States  

View report >

Related Market Segments :

Cancer Immunotherapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.